Literature DB >> 17215572

Indoxyl sulfate and atherosclerotic risk factors in hemodialysis patients.

Kentaro Taki1, Yoshinari Tsuruta, Toshimitsu Niwa.   

Abstract

BACKGROUND: Indoxyl sulfate is a uremic toxin that accelerates the progression of chronic kidney disease (CKD). Serum levels of indoxyl sulfate are increased in dialysis patients. It was reported that indoxyl sulfate plays a role in endothelial dysfunction in uremic patients, and stimulates proliferation of rat vascular smooth muscle cells (VSMC). We examined associations between indoxyl sulfate and several markers related to atherosclerosis.
METHODS: The association between indoxyl sulfate and atherosclerotic risk factors was studied in 224 hemodialysis (HD) patients (123 male, 101 female). Serum levels of indoxyl sulfate were measured by using high-performance liquid chromatography (HPLC).
RESULTS: There were significant differences in serum levels of creatinine, calcium x phosphate and pentosidine between high- and low-indoxyl sulfate level groups. Indoxyl sulfate showed significant positive correlations with pentosidine, creatinine, and protein catabolic rate, and a significant negative correlation with high-density lipoprotein (HDL) cholesterol. Further, pentosidine, creatinine, and HDL-cholesterol were independently associated with indoxyl sulfate by multiple linear regression analysis.
CONCLUSION: In addition to creatinine, pentosidine and HDL-cholesterol, the risk factors of atherosclerosis, were associated with indoxyl sulfate in HD patients. Indoxyl sulfate may be involved in the pathogenesis of atherosclerosis. 2007 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17215572     DOI: 10.1159/000098542

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN: 0250-8095            Impact factor:   3.754


  26 in total

Review 1.  Normal and pathologic concentrations of uremic toxins.

Authors:  Flore Duranton; Gerald Cohen; Rita De Smet; Mariano Rodriguez; Joachim Jankowski; Raymond Vanholder; Angel Argiles
Journal:  J Am Soc Nephrol       Date:  2012-05-24       Impact factor: 10.121

2.  Indoxyl sulfate-induced endothelial dysfunction in patients with chronic kidney disease via an induction of oxidative stress.

Authors:  Mina Yu; Young Ju Kim; Duk-Hee Kang
Journal:  Clin J Am Soc Nephrol       Date:  2010-09-28       Impact factor: 8.237

3.  p-Cresylsulfate and indoxyl sulfate level at different stages of chronic kidney disease.

Authors:  Cheng-Jui Lin; Han-Hsiang Chen; Chi-Feng Pan; Chih-Kuang Chuang; Tuen-Jen Wang; Fang-Ju Sun; Chih-Jen Wu
Journal:  J Clin Lab Anal       Date:  2011       Impact factor: 2.352

4.  Association of indoxyl sulfate with heart failure among patients on hemodialysis.

Authors:  Xue-Sen Cao; Jun Chen; Jian-Zhou Zou; Yi-Hong Zhong; Jie Teng; Jun Ji; Zhang-Wei Chen; Zhong-Hua Liu; Bo Shen; Yu-Xin Nie; Wen-Lv Lv; Fang-Fang Xiang; Xiao Tan; Xiao-Qiang Ding
Journal:  Clin J Am Soc Nephrol       Date:  2014-10-20       Impact factor: 8.237

Review 5.  The contributory role of gut microbiota in cardiovascular disease.

Authors:  W H Wilson Tang; Stanley L Hazen
Journal:  J Clin Invest       Date:  2014-10-01       Impact factor: 14.808

6.  Nitric oxide counters the inhibitory effects of uremic toxin indoxyl sulfate on endothelial cells by governing ERK MAP kinase and myosin light chain activation.

Authors:  Sourabh Kharait; Daniel J Haddad; Matthew L Springer
Journal:  Biochem Biophys Res Commun       Date:  2011-05-20       Impact factor: 3.575

Review 7.  Mechanism by which chronic kidney disease causes cardiovascular disease and the measures to manage this phenomenon.

Authors:  Eiji Kusano
Journal:  Clin Exp Nephrol       Date:  2011-06-01       Impact factor: 2.801

8.  Alleviation of cisplatin-induced acute kidney injury using phytochemical polyphenols is accompanied by reduced accumulation of indoxyl sulfate in rats.

Authors:  Masahiro Kusumoto; Hiroki Kamobayashi; Daisuke Sato; Megumi Komori; Misato Yoshimura; Akinobu Hamada; Yukimasa Kohda; Kimio Tomita; Hideyuki Saito
Journal:  Clin Exp Nephrol       Date:  2011-08-23       Impact factor: 2.801

Review 9.  Pharmacologic management of the cardiorenal syndrome in heart failure.

Authors:  Henry Krum; Pupalan Iyngkaran; Suree Lekawanvijit
Journal:  Curr Heart Fail Rep       Date:  2009-06

10.  Pre-, pro-, and synbiotics: do they have a role in reducing uremic toxins? A systematic review and meta-analysis.

Authors:  Megan Rossi; Kerenaftali Klein; David W Johnson; Katrina L Campbell
Journal:  Int J Nephrol       Date:  2012-12-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.